Period:
Draw Mode:
| Volume | 211,331 |
|
|||||
| News | - | ||||||
| Day High | 0.531 | Low High |
|||||
| Day Low | 0.42 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| AIM ImmunoTech Inc | AIM | AMEX | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.041 | -7.72% | 0.49 | 14:16:16 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.5195 | 0.42 | 0.531 | 0.531 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 314 | 211,331 | $ 0.4722276 | $ 99,796 | - | 0.291 - 0.8359 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 14:16:16 | 200 | $ 0.49 | USD |
AIM ImmunoTech Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 23.85M | 48.67M | - | 141k | -19.45M | -0.40 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
AIM ImmunoTech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AIM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.598 | 0.60 | 0.42 | 0.5522369 | 69,606 | -0.108 | -18.06% |
| 1 Month | 0.647 | 0.68 | 0.42 | 0.606859 | 117,307 | -0.157 | -24.27% |
| 3 Months | 0.69 | 0.7487 | 0.42 | 0.6322094 | 121,788 | -0.20 | -28.99% |
| 6 Months | 0.41 | 0.7487 | 0.385 | 0.5674408 | 114,468 | 0.08 | 19.51% |
| 1 Year | 0.63 | 0.8359 | 0.291 | 0.5384969 | 156,411 | -0.14 | -22.22% |
| 3 Years | 2.25 | 3.06 | 0.291 | 1.95 | 632,032 | -1.76 | -78.22% |
| 5 Years | 1.96 | 8.75 | 0.291 | 2.55 | 1,632,275 | -1.47 | -75.0% |
AIM ImmunoTech Description
| AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19. |